Credit Suisse Downgrades McKesson (MCK) to Underperform
- Wall Street surges to new highs; transports set record
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Costco Wholesale (COST) Tops Q1 EPS by 5c; Comps Up 1%, 2% Ex-Gas
- After-Hours Stock Movers 12/07: (VYGR) (LULU) (HRB( Higher; (OHRP) (VRNT) (CMTL) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Credit Suisse downgraded McKesson (NYSE: MCK) from Neutral to Underperform with a price target of $131.00 (from $150.00) on capital efficiency discrepancy.
Analyst Robert Willoughby commented, "MCK pointed to irrational industry pricing for a second negative EPS revision this year. AmerisourceBergen and Cardinal Health also noted weaker pricing, but with competitive advantages in generic sourcing capabilities from an invested capital standpoint, their practices seem more consistent with maintaining high ROICs. MCK's average invested capital base equals the sum for its two competitors, yet its NOPAT grew at about half the CAGR over FY12-FY16, with higher capital requirements and lower earnings ahead, in our view. Longer term, it may benefit more from owning sourcing capabilities outright, but Celesio contributions, higher deal spend/capital needs, and distortions from the pending Technology Solutions exit limit our near term enthusiasm."
Shares of McKesson closed at $141.33 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Credit Suisse Downgrades NetApp (NTAP) to Underperform
- RBC Capital Downgrades Concordia Healthcare (CXRX) to Underperform, $1 PT
- Credit Suisse Downgrades Kellogg (K) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades, Hot Downgrades
Related EntitiesCredit Suisse, Earnings, Robert Willoughby
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!